Clinical trial
The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Preserved Ejection Fraction - a Randomized Controlled Trial
NCT06249945 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Preserved Ejection Fraction - a Randomized Controlled Trial
- Lead sponsor
- National Taiwan University Hospital
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- March 5, 2024
- Completion date
- December 31, 2030
- Enrollment
- 150 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
end stage renal disease on dialysis, heart failure with preserved ejection fraction